Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 11/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | APOB | P04114 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12185492 | 0.94 | MTTP (0.38) | MTTPSMOAPOB | |
| SCHEMBL14790145 | 0.94 | MTTP (0.38) | MTTPSMOAPOB | |
| SCHEMBL14777753 | 0.93 | MTTP (0.39) | MTTPRXFP1ADAMTS7PTGDR2KMT2A | |
| SCHEMBL14790203 | 0.93 | KMT2A (0.36) | KMT2AALDH1A1HPGD | |
| SCHEMBL12185931 | 0.92 | MTTP (0.40) | MTTPADAMTS7APOB | |
| SCHEMBL12185538 | 0.92 | MTTP (0.40) | MTTPADAMTS7APOB | |
| SCHEMBL12185907 | 0.90 | BRPF1 (0.33) | KMT2AALDH1A1HPGD | |
| SCHEMBL14778356 | 0.90 | MTTP (0.37) | MTTPAPOB | |
| SCHEMBL2598182 | 0.89 | MTTP (0.37) | MTTPKMT2AALDH1A1HPGD | |
| SCHEMBL12185456 | 0.89 | SMO (0.39) | MTTPSMOAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | claimed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | APOB, MTTP, HADHB | MTTP 2/4885RXFP1 4055/4885ADAMTS7 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.